Results 111 to 120 of about 10,858 (213)

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial [PDF]

, 2018
BACKGROUND: Weekends off antiretroviral therapy (ART) may help engage HIV-1-infected young people facing lifelong treatment. BREATHER showed short cycle therapy (SCT; 5 days on, 2 days off ART) was non-inferior to continuous therapy (CT) over 48 weeks ...
Babiker, A, Bologna, R, BREATHER (PENTA 16) Trial Group, ., Bunupuradah, T, Butler, K, Chalermpantmetagul, S, Compagnucci, A, Cressey, TR, Flynn, PM, Ford, D, Giaquinto, C, Gibb, DM, Harper, L, Kaudha, E, Klein, N, Montero, S, Moore, CL, Musiime, V, Nanduudu, A, Nastouli, E, Ramos Amador, JT, Riault, Y, Saïdi, Y, Scott, K, Turkova, A, Volokha, A, Welch, SB   +26 more
core  

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Health Science Reports
Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences.
Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke   +4 more
doaj   +1 more source

Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States

Infectious Diseases and Therapy
Introduction HIV/hepatitis B virus (HBV) coinfection elevates the risk of liver-related complications compared to HIV or HBV mono-infections. While some antiretroviral therapy (ART) regimens slow liver disease progression, the long-term effects of ...
Ching-Yi Chuo, Woodie Zachry, Melanie de Boer, Laura Telep, Li Tao   +4 more
doaj   +1 more source

Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana [PDF]

, 2015

core   +1 more source

Tenofovir alafenamide/tenofovir disoproxil fumarate

Reactions Weekly, 2021
openaire   +1 more source

The benefits and risks of PrEP and kidney function. [PDF]

, 2016
Mocroft, A, Ryom, L
core   +1 more source

Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report [PDF]

, 2016
Kentaro Iwata, Manabu Nagata, Shinichi Nishi, Shuhei Watanabe   +3 more
core   +1 more source

Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate. [PDF]

Neurol Neuroimmunol Neuroinflamm
Torkildsen Ø, Bru ANS, Behzadi GIN, Myhr KM.   +3 more
europepmc   +1 more source

Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED. [PDF]

J Acquir Immune Defic Syndr
Nguyen T, Chae JW, Ziemba L, Coletti A, Knowles K, Johnston B, Jean-Philippe P, Mhembere T, Chawana T, Wabwire D, Korutaro V, Moyo S, Mandima P, Sibisi S, Violari A, Hanley S, Mmbaga B, Masheto G, Ponatshego P, Theron G, Naik SN, Shapiro R, Lockman S, Chinula L, Momper JD, IMPAACT 2010/VESTED Protocol Team.   +25 more
europepmc   +1 more source

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use [PDF]

, 2015

core   +1 more source